FOXN1 and glioma: Both glioma cell lines (U87MG and its STAT3 knockout variant U87MG-STAT3KO) were next implanted into the Foxn1-nude mice and for 28 days the tumor growth was monitored with simultaneous administration (from 15th day after implantation) of TMZ at 0.9 mg/kg concentration.